Demyelinating events following anti‐tumor necrosis factor alpha therapy: Rare but challenging to treat-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Demyelinating events following anti‐tumor necrosis factor alpha therapy: Rare but challenging to treat

Published:2022-03-21 Issue:7 Volume:29 Page:2047-2055
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Euro J of Neurology

Author:

Kalén Erik¹^ORCID,Piehl Fredrik²³,Andersson Magnus²³^ORCID

Affiliation:

1. Department of Biomedical and Clinical Sciences Linköping University Hospital Linkoping Sweden

2. Department of Clinical Neuroscience Karolinska Institute Stockholm Sweden

3. Department of Neurology Karolinska University Hospital and Academic Specialist Center, Stockholm Health Services Stockholm Sweden

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ene.15318

Reference24 articles.

1. Tumor necrosis factor receptor-2 (TNFR2): an overview of an emerging drug target

2. Tumor Necrosis Factor-alpha and the Roles it Plays in Homeostatic and Degenerative Processes Within the Central Nervous System

3. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

4. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

5. Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple sclerosis associated with adalimumab use in ankylosing spondylitis;Neurological Sciences;2024-04-10

2. Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers;RMD Open;2023-02

3. Therapeutic consequences in patients with both inflammatory rheumatic diseases and multiple sclerosis;Rheumatology;2022-11-28

4. The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases;Frontiers in Immunology;2022-09-29

5. Adalimumab/etanercept/infliximab;Reactions Weekly;2022-08-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3